PEPTIDESTAT
ApprovedClinical / approved drugSubcutaneousEvidence 4/5

Teriparatide

Also known as: Forteo, Bonsity, PTH 1-34

Once-daily injection produces intermittent activation of the PTH1 receptor on osteoblasts, preferentially stimulating bone formation over resorption to increase bone mass.

Read guideBuy / compare source
Teriparatide
Drug class
Parathyroid hormone analog; anabolic (bone-forming) osteoporosis agent
Primary targets
PTH1 receptor (PTH/PTHrP receptor), osteoblasts
Dose reference
20 mcg subcutaneously once daily (labeled dose for Forteo and Bonsity; reference figure, not a recommendation)
Half-life
Approximately 1 hour after subcutaneous injection (a few minutes after IV); Forteo label
Developer / origin
Eli Lilly (Forteo); Pfenex/Alvogen (Bonsity)
Reference year
2002
Evidence score
4/5 - Approved with strong randomized fracture-prevention evidence

Approved uses

  • Treatment of postmenopausal women with osteoporosis at high risk for fracture
  • To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture
  • Treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture
Evidence 4/5

Approved with strong randomized fracture-prevention evidence

Teriparatide is FDA-approved and supported by randomized controlled trials showing substantial reductions in vertebral and nonvertebral fractures in high-fracture-risk osteoporosis, tempered by an early-stopped pivotal trial, a 2-year duration caution, and post-treatment bone-mass loss.

Investigational compound with human randomized or phase 2/3 evidence.

Evidence basis

  • Neer et al. NEJM 2001 Fracture Prevention Trial (n=1,637): ~65% reduction in new vertebral fractures and ~53% reduction in nonvertebral fragility fractures vs placebo
  • Saag et al. NEJM 2007: teriparatide produced greater BMD gains and fewer new vertebral fractures than alendronate in glucocorticoid-induced osteoporosis
  • FDA approval of Forteo (2002) and Bonsity (2019) with three labeled high-fracture-risk indications
  • Gilsenan et al. JBMR 2021 15-year surveillance study found no increased osteosarcoma risk (SIR ~0.72), leading FDA to remove the boxed warning in 2020
  • Limits: pivotal trial stopped early due to rat carcinogenicity findings; efficacy/safety not evaluated beyond 2 years; gains erode after stopping without a follow-on antiresorptive

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Teriparatide guides

Read the matching guide or adjacent research pages for more context.

Teriparatide Peptide: Forteo, Bonsity, PTH(1-34) for OsteoporosisTeriparatide is an FDA-approved recombinant PTH(1-34) peptide that builds bone in high-fracture-risk osteoporosis, with strong trial evidence and a distinctive safety history.Abaloparatide Peptide: Tymlos, PTHrP Analog Uses and Safety LimitsAbaloparatide is an FDA-approved PTHrP(1-34) analog peptide that builds bone in high-risk osteoporosis, backed by the ACTIVE and ATOM trials with clear duration and safety limits.Atosiban Peptide: Tractocile, Oxytocin Antagonist Tocolytic for Preterm LaborAtosiban is an EU-approved oxytocin and vasopressin receptor antagonist peptide used intravenously as a short-term tocolytic to delay preterm labor.Bivalirudin Peptide: Angiomax Direct Thrombin Inhibitor GuideBivalirudin is an FDA-approved, hirudin-derived bivalent direct thrombin inhibitor used as a short-acting intravenous anticoagulant during percutaneous coronary intervention.

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open toolPeptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open toolPeptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open toolPeptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Larazotide

Larazotide acetate, AT-1001

2/5
Clinical / approved drugInvestigational

An oral, gut-restricted peptide that antagonizes zonulin signaling to limit gluten-driven intestinal tight-junction permeability in celiac disease.

DetailsGuide

Lanreotide

Somatuline Depot, Somatuline Autogel

5/5
Clinical / approved drugApproved

Lanreotide binds with high affinity to somatostatin receptors 2 and 5, mimicking native somatostatin to suppress growth hormone, IGF-1 and various neuroendocrine and gut hormones.

DetailsGuide
4/5
Clinical / approved drugApproved

Abaloparatide is a PTHrP(1-34) analog that agonizes the PTH1 receptor with preference for its transient RG conformation, activating cAMP signaling to stimulate osteoblast-driven new bone formation.

DetailsGuide

Calcitonin

Miacalcin, Fortical, salmon calcitonin

3/5
Clinical / approved drugApproved

Calcitonin activates the calcitonin receptor on osteoclasts to inhibit bone resorption and lower blood calcium, with additional actions on the kidney and gastrointestinal tract.

DetailsGuide

Research & educational purposes only

The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.